PROCRYSTAL Crystallisation towards efficient and sustainable biomanufacturing
- Coordinator
- Universidade Do Minho, Portugal
- Runs
- 1 January 2025 to 31 December 2028
- Status
- Running
- EU funding
- €3.3m
- Total cost
- —
- Partners
- 17 organisations in 8 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101169471
What the project is doing
In the project's own words, from its summary on CORDIS.
Downstream processing (DSP) of biopharmaceuticals is dominated by chromatographic steps which suffer from low throughput, poor scalability and elevated energy consumption, as well as high equipment and materials costs. To this is added the low stability and high degradability of liquid formulations. The training program ""Crystallisation towards efficient and sustainable biomanufacturing"" (PROCRYSTAL) vision is that of crystallisation as a simple, sustainable, cost-efficient and scalable alternative to current DSP techniques and liquid formulations, once it allows to separate, purify and stabilise in a single step.
Nevertheless, integrated training to exploit biocrystallisation full potential is currently not available, only fragmented research activities. Within this training program, 13 Doctoral candidates (DCs) are expected to go beyond current practise to respond to the near future biopharma manufacturing needs. And only possible leveraged by the expertise conveyed in this consortium on biomolecules crystallisation, biochemistry, chemical and process engineering as well as advanced modelling.
The PROCRYSTAL training program for the DCs has been framed with special attention to fundamental understanding of the underlying phenomena, from the molecular scale to process scale, and advanced experimental and modelling techniques specific to crystallisation technology. The DCs will acquire a wide range of subject specific and general transferable skills, in an interdisciplinary and inter-sectoral environment and by multinational collaboration which enhances the early-career DCs long term employability and competitiveness.""
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universidade Do Minho | Braga | Portugal | Coordinator |
| Janssen Pharmaceutica NV | Beerse | Belgium | Participant |
| Katholieke Universiteit Leuven | Leuven | Belgium | Participant |
| Secoya Technologies | Ottignies-Louvain-La-Neuve | Belgium | Participant |
| Vrije Universiteit Brussel | Bruxelles / Brussel | Belgium | Participant |
| Chimikotechnologitchen I Metalurgitchen Universitet | Sofia | Bulgaria | Participant |
| Agencia Estatal Consejo Superior De Investigaciones Cientificas | Madrid | Spain | Participant |
| Universidad De Granada | Granada | Spain | Associatedpartner |
| Centre National De La Recherche Scientifique CNRS | Paris | France | Participant |
| Lamark Biotech SAS | Évry-Courcouronnes, Paris Region | France | Associatedpartner |
| Sanofi-Aventis Recherche & Developpement | Gentilly | France | Associatedpartner |
| Universite D'aix Marseille | Marseille | France | Associatedpartner |
| Budapesti Muszaki Es Gazdasagtudomanyi Egyetem | Budapest | Hungary | Participant |
| Eos SRL | Milano | Italy | Associatedpartner |
| Universidade Nova De Lisboa | Lisboa | Portugal | Associatedpartner |
| Imperial College of Science Technology and Medicine | London | United Kingdom | Associatedpartner |
| Molecular Dimensions Limited | Newmarket | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI